Shenouda Maged 4
4 · RELMADA THERAPEUTICS, INC. · Filed Sep 11, 2024
Insider Transaction Report
Form 4
Shenouda Maged
Chief Financial Officer
Transactions
- Purchase
Common Stock
2024-09-09$2.55/sh+8,194$20,895→ 43,097 total - Purchase
Common Stock
2024-09-10$2.73/sh+21,118$57,652→ 64,215 total - Purchase
Common Stock
2024-09-11$2.95/sh+24,120$71,154→ 88,335 total
Footnotes (4)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $2.49 to $2.60 per share, inclusive.
- [F3]Purchase prices range from $2.70 to $2.75 per share, inclusive.
- [F4]Purchase prices range from $2.79 to $3.05 per share, inclusive.